EP0131611A1 - $g(b)-LACTAM ANTIBACTERIAL AGENTS - Google Patents
$g(b)-LACTAM ANTIBACTERIAL AGENTSInfo
- Publication number
- EP0131611A1 EP0131611A1 EP84900522A EP84900522A EP0131611A1 EP 0131611 A1 EP0131611 A1 EP 0131611A1 EP 84900522 A EP84900522 A EP 84900522A EP 84900522 A EP84900522 A EP 84900522A EP 0131611 A1 EP0131611 A1 EP 0131611A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- formula
- compound
- acid
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the compounds of the present invention may contain both an amino group and/or a carboxyl group and may, therefore, exist as the zwitterion or may form salts with suitable acids or bases.
- the formamido group can exist in two preferred conformations, those wherein the hydrogen atoms of the -NH-CHO are, cis- or trans-, of which the cisconformation normally predominates.
- the ⁇ -lactam antibiotic compounds of the present invention are intended for use in pharmaceutical compositions it will readily be understood that they are each provided in substantially pure form, for example at least 50% pure, more suitably at least 75% pure and preferably at least 95% pure (% are on a wt/wt basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutial compositions. Although the purity of intermediate compounds of the present invention is less critical it will readily be understood that the substantially pure form is preferred as for the ⁇ -lactam antibiotic compounds. Preferably, whenever possible, the compounds of the present invention are obtained in crystalline form.
- R 14 represents hydrogen, C 1-6 alkyl, substituted alkyl, aryl, or aralkyl
- R 15 and R 16 are the same or different and represent hydrogen, C 1-6 alkyl, substituted alkyl, halogen, amino, hydroxy or
- Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
- the present invention also includes a method of treating bacterial infections in humans and animals which comprises the administration of a therapeutically effective amount of an antibiotic compound of this invention.
- the antibiotic compounds of the present invention are active against a broad range of gram positive and gram negative bacteria, in particular they are useful for treatment of respiratory tract and urinary tract infections in humans and mastitis in cattle.
- a particular advantage of the antibacterially active compounds of this invention is their stability to ⁇ -lactamase enzymes and they are therefore effective against ⁇ -lactamase producing organisms.
- Suitable formylating agents include mixed anhydrides such as formic acetic anhydride.
- the reaction may suitably be carried out in a temperature in the range -50°C to 30oC in aprotic solvent such as, for example, dichloromethane, chloroform, dimethylformamide, tetrahydrofuran, hexamethylphosphoramide, or dimethylsulphoxide, in the presence of a tertiary base.
- a preferred tertiary base employed in the reaction is a base of the pyridine type, such as pyridine, lutidine or picoline.
- R 19 is C 1-6 alkyl, aryl or benzyl; with anhydrous ammonia , an ammonium salt or an amine of the formula (XII)
- Suitable N-acylating derivatives include an acid halide, preferably the acid chloride or bromide.
- Acylation with an acid halide may be affected in the presence of an acid binding agent for example, tertiary amine (such as triethylamine, pyridine or dimethylaniline), an inorganic base (such as calcium carbonate or sodium bicarbonate) or an oxirane, which binds hydrogen halide liberated in the acylation reaction.
- the oxirane is preferably a (C 1-6 )1,2-alkylene oxide - such as ethylene oxide or propylene oxide.
- the thiol HetSH may be reacted as the free compound or a salt with an alkali metal such as sodium or potassium.
- This reaction is desirably conducted in a solvent.
- a solvent for example, use can be made of water, or organic solvents inert to the starting compounds, such as dimethylformamide, dimethylacetamide, dioxane, acetone, alcohol, 1,2-dichloroethane, acetonitrile, dimethylsulfoxide or tetrahydrofuran, or mixtures thereof.
- the reaction temperature and time depend, among other factors, upon the starting compounds and solvent to be employed but generally the reaction is carried out at a selected temperature within the range of 0 to 100°C for a selected time of a few hours to several days.
- the reaction is desirably conducted between pH 3 and 7.
- Example 1 illustrates the preparation and use of the compounds of the present invention.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8301694 | 1983-01-21 | ||
GB838301694A GB8301694D0 (en) | 1983-01-21 | 1983-01-21 | Beta-lactam antibacterial agents |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0131611A1 true EP0131611A1 (en) | 1985-01-23 |
Family
ID=10536717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP84900522A Ceased EP0131611A1 (en) | 1983-01-21 | 1984-01-19 | $g(b)-LACTAM ANTIBACTERIAL AGENTS |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0131611A1 (ja) |
JP (1) | JPS60500497A (ja) |
GB (1) | GB8301694D0 (ja) |
WO (1) | WO1984002911A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL83549A (en) * | 1987-08-16 | 1992-08-18 | Yossi Matias | Video scrambling apparatus and method based on space filling curves |
US8883772B2 (en) | 2007-10-09 | 2014-11-11 | Sopharmia, Inc. | Broad spectrum beta-lactamase inhibitors |
EP3441071A1 (en) | 2013-03-12 | 2019-02-13 | Gladius Pharmaceuticals Corporation | Derivatized cephalosporins |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0066373B1 (en) * | 1981-05-22 | 1985-03-20 | Beecham Group Plc | Beta-lactam derivatives, a process for their preparation and compositions containing them |
EP0071395B1 (en) * | 1981-07-25 | 1988-08-10 | Beecham Group Plc | Beta-lactam antibacterial agents |
-
1983
- 1983-01-21 GB GB838301694A patent/GB8301694D0/en active Pending
-
1984
- 1984-01-19 EP EP84900522A patent/EP0131611A1/en not_active Ceased
- 1984-01-19 WO PCT/GB1984/000010 patent/WO1984002911A1/en not_active Application Discontinuation
- 1984-01-19 JP JP59500620A patent/JPS60500497A/ja active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO8402911A1 * |
Also Published As
Publication number | Publication date |
---|---|
GB8301694D0 (en) | 1983-02-23 |
JPS60500497A (ja) | 1985-04-11 |
WO1984002911A1 (en) | 1984-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4539149A (en) | β-Lactam antibacterial agents | |
EP0114752B1 (en) | Beta-lactam antibacterial agents | |
US4122086A (en) | Isopenicillins | |
US4820701A (en) | Penam derivatives | |
US4166816A (en) | Methods and intermediates for preparing cis-4-oxoazetidine intermediates | |
US4684639A (en) | Antibacterial penicillins and cephalosporins | |
EP0114750A2 (en) | Beta-lactam antibacterial agents | |
EP0088488B1 (en) | Antibacterial agents, their preparation and use | |
EP0131611A1 (en) | $g(b)-LACTAM ANTIBACTERIAL AGENTS | |
NZ225875A (en) | Cephalosporin derivatives having a radical substituted by 4-ethyl(2,3-dioxopiperazin-1-yl)carbonylamino-acetamido group in the 7-position: preparatory processes and pharmaceutical compositions | |
US4308259A (en) | Penicillin derivatives | |
US4661480A (en) | Formamido oxacephems | |
US4416883A (en) | Penicillin derivatives | |
EP0066373B1 (en) | Beta-lactam derivatives, a process for their preparation and compositions containing them | |
US4349551A (en) | Penicillin derivatives and compositions containing them | |
US4540688A (en) | β-Lactam antibiotics | |
US4835150A (en) | Cephem compounds | |
EP0084948B1 (en) | Penicillin derivatives | |
EP0166377A1 (en) | Process for the preparation of beta-lactam compounds and intermediates therefor | |
EP0167011A2 (en) | Beta-lactam compounds, intermediates thereof, their use in preparing beta-lactams having a diketopiperazine group | |
HUT53651A (en) | Process for producing new beta-lactam compounds and pharmaceutical compositions comprising same | |
IE53889B1 (en) | Beta-lactam antibacterial agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19840828 |
|
AK | Designated contracting states |
Designated state(s): CH DE FR GB LI NL |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 19871001 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: MILNER, PETER, HENRY |